The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash ...

Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it ...

Ousted Venezuelan President Nicolás Maduro pleaded not guilty to narcotrafficking charges during his arraignment in U.S. federal court Monday, defiantly telling a judge that he was still the head of ...

Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion. "Immediately upon close, this ...

Palisade Bio’s bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which ...

The battle-scarred biotech BioMarin Pharmaceutical on Friday announced a $4.8 billion deal to acquire a smaller biotech, Amicus Therapeutics, which sells two drugs that treat rare genetic disorders.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...